Neuroscience

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am…

1 year ago

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)…

1 year ago

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase…

1 year ago

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

1 year ago

Long-time Collaborators Botond Roska and José-Alain Sahel Win International Prize for Translational Neuroscience

J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring…

1 year ago

BrainsWay Announces Significant Expansion in Western and Central U.S.

30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --…

1 year ago

Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE…

1 year ago

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that…

1 year ago

Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

The Company expands technology for patients with obsessive-compulsive disorderMALVERN, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…

1 year ago